IBDV remains one of the most challenging poultry health concerns, and it is evolving due to genetic variation.6
Flock health managers rely heavily on recombinant vector vaccines with a herpesvirus of turkeys (HVT) backbone as valuable tools for protecting against both Marek’s disease and IBDV, among other viral challenges. About 60% of the U.S. layer population was vaccinated with a vector HVT‑IBD vaccine as of 2019.9
Timing is everything in egg production, from the day pullet chicks hatch throughout the hen’s entire production cycle. Poulvac® Procerta™ HVT‑IBD protects chicks fast and delivers strong overall protection to common IBDV challenges, providing fast, long‑lasting protection.4,10-11
FAST PROTECTION AGAINST CRITICAL LAYER IBDV CHALLENGES AT DAY 14
Poulvac Procerta HVT-IBD has demonstrated strong protection against various IBDV challenges common to the U.S. layer industry.
- In a study with no maternal antibodies present, Poulvac Procerta HVT-IBD provided 98% protection against a Day 14 classic IBDV challenge, based on acute bursal lesions.10
- In a study assessing bursal atrophy in pullets, Poulvac Procerta HVT-IBD provided 100% protection following a Day 14 classic IBDV challenge.4
- Poulvac Procerta HVT-IBD also demonstrated 90% efficacy at Day 14 against a very virulent IBDV challenge (California isolate) using subcutaneous injection.11
Download Studies
“IBDV remains a leading challenge to the commercial egg industry.”
John Brown
DVM
Senior Technical Services Veterinarian, Zoetis